research
oaioai:cronfa.swan.ac.uk:cronfa18273

Inpatient Coronary Angiography and Revascularisation following Non-ST-Elevation Acute Coronary Syndrome in Patients with Renal Impairment: A Cohort Study Using the Myocardial Ischaemia National Audit Project

Abstract

Guidelines support early invasive management that includes coronary angiography and revascularisation) for non-ST-elevation acute coronary syndrome (NSTE-ACS) in patients with renal impairment. We described NHS practice to determine whether the severity of renal dysfunction influenced the provision of angiography and modified the association between early revascularisation and survival.We anaylsed a cohort, using multivariable logistic regression and propensity score analyses, from the Myocardial Ischaemia National Audit Project (MINAP) for patients with NSTE-ACS in England or Wales between 2008 and 2010. Of 35 881 patients diagnosed with NSTE-ACS, eGFR of less than 60 ml/minute/1.73 m2 was present in 15 680 (43.7%).There was a stepwise decline in the odds of undergoing inpatient angiography with worsening renal dysfunction.Compared with an eGFR,of more than 90 ml/minute/1.73 m2, patients with an eGFR between 45–59 ml/minute/1.73 m2 were 33% less likely to undergo angiography (adjusted OR 0.67, 95% CI 0.55–0.81); those with an eGFR less than 30/minute/1.73 m2 had a 64% reduction in odds of undergoing angiography (adjusted OR 0.36, 95%CI 0.29–0.43). Of 16 646 patients who had inpatient coronary angiography, 58.5% underwent inpatient revascularisation. After adjusting for co-variables, inpatient revascularisation was associated with approximately a 30% reduction in death within 1 year compared with thosemanaged medically after coronary angiography (adjusted OR 0.66, 95%CI 0.57–0.77), with no evidence of modification byrenal function (p interaction = 0.744).Early revascularisation offers a similar survival benefit in patients with and without renal dysfunction, yet renal impairment is an important determinant of the provision of coronary angiography following NSTE-ACS. A randomised controlled trial is needed to evaluate the efficacy of an early invasive approach in patients with severe renal dysfunction to ensure that all patients who may benefit are offered this treatment option

Similar works

Full text

thumbnail-image

Cronfa at Swansea University

Provided a free PDF
oaioai:cronfa.swan.ac.uk:cronfa18273Last time updated on 3/6/2017View original full text link

This paper was published in Cronfa at Swansea University.

Having an issue?

Is data on this page outdated, violates copyrights or anything else? Report the problem now and we will take corresponding actions after reviewing your request.